Insulet Corporation vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Acton MA tubeless insulin pump (NASDAQ: PODD) $2.18B FY2024 revenue (+21%); Omnipod 5 automated insulin delivery with Dexcom/Libre integration, type 2 expansion, competing with Medtronic MiniMed and Tandem.
About
Insulet Corporation is an Acton, Massachusetts-based medical device company — publicly traded on the NASDAQ (NASDAQ: PODD) as an S&P 500 Health Care component — developing, manufacturing, and commercializing the Omnipod insulin delivery system: a tubeless, wearable, waterproof insulin pump patch worn directly on the body without tubing connections to a separate controller, automatically delivering insulin to people with type 1 and type 2 diabetes through approximately 5,000 employees globally. In fiscal year 2024, Insulet reported revenues of $2.18 billion (+21% year-over-year), driven by Omnipod 5 (Omnipod's automated insulin delivery — AID — system integrating with Dexcom CGM and Abbott FreeStyle Libre sensors to automatically adjust insulin delivery based on real-time glucose readings without manual user input), which drove international expansion in Europe and adoption in type 2 diabetes patients who previously used multiple daily injections rather than insulin pumps. CEO Jim Hollingshead has accelerated Omnipod's differentiation through the automated insulin delivery positioning: Omnipod 5's algorithm automatically modulates basal insulin rates every 5 minutes based on continuous glucose monitor readings — reducing A1c levels and time-in-hypoglycemia without requiring the user to manually program correction boluses for most scenarios — transforming diabetes management from active self-management to a background automated process that dramatically improves quality of life for insulin-dependent diabetics.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Insulet Corporation vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.